These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 23385248)
1. MDR-TB has new drug foe after fast-track approval. Voelker R JAMA; 2013 Feb; 309(5):430. PubMed ID: 23385248 [No Abstract] [Full Text] [Related]
2. Approval of a tuberculosis drug based on a paradoxical surrogate measure. Avorn J JAMA; 2013 Apr; 309(13):1349-50. PubMed ID: 23430122 [No Abstract] [Full Text] [Related]
3. Bedaquiline (Sirturo) for multidrug-resistant tuberculosis. Med Lett Drugs Ther; 2013 Aug; 55(1423):66-8. PubMed ID: 23959388 [No Abstract] [Full Text] [Related]
5. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis. Nagabushan H; Roopadevi HS J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373 [TBL] [Abstract][Full Text] [Related]
6. Race heats up for first-to-market drugs for resistant tuberculosis. Willyard C Nat Med; 2012 Aug; 18(8):1157. PubMed ID: 22869168 [No Abstract] [Full Text] [Related]
7. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Worley MV; Estrada SJ Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970 [TBL] [Abstract][Full Text] [Related]
8. Public-private partnership tackles TB challenges in parallel. Webb S Nat Rev Drug Discov; 2009 Aug; 8(8):599-600. PubMed ID: 19644463 [TBL] [Abstract][Full Text] [Related]
9. TMC207 becomes bedaquiline, a new anti-TB drug. Palomino JC; Martin A Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736 [TBL] [Abstract][Full Text] [Related]
10. Unorthodox approach to the development of a new antituberculosis therapy. Barry CE N Engl J Med; 2009 Jun; 360(23):2466-7. PubMed ID: 19494223 [No Abstract] [Full Text] [Related]
11. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults. Gras J Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939 [TBL] [Abstract][Full Text] [Related]
12. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Chahine EB; Karaoui LR; Mansour H Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600 [TBL] [Abstract][Full Text] [Related]
14. Anything to Stay Alive: The Challenges of a Campaign for an Experimental Drug. Geffen N Dev World Bioeth; 2016 Apr; 16(1):45-54. PubMed ID: 25982452 [TBL] [Abstract][Full Text] [Related]
15. Benefit-Risk Analysis for Decision-Making: An Approach. Raju GK; Gurumurthi K; Domike R Clin Pharmacol Ther; 2016 Dec; 100(6):654-671. PubMed ID: 27627788 [TBL] [Abstract][Full Text] [Related]
16. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Udwadia ZF; Amale RA; Mullerpattan JB Int J Tuberc Lung Dis; 2014 Nov; 18(11):1315-8. PubMed ID: 25299863 [TBL] [Abstract][Full Text] [Related]
17. Microbiology. TB--a new target, a new drug. Cole ST; Alzari PM Science; 2005 Jan; 307(5707):214-5. PubMed ID: 15653490 [No Abstract] [Full Text] [Related]
18. Delamanid: first global approval. Ryan NJ; Lo JH Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253 [TBL] [Abstract][Full Text] [Related]
19. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333 [No Abstract] [Full Text] [Related]
20. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Kakkar AK; Dahiya N Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]